Cargando…

Immunotherapy for malignant glioma

Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12–15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Suryadevara, Carter M., Verla, Terence, Sanchez-Perez, Luis, Reap, Elizabeth A., Choi, Bryan D., Fecci, Peter E., Sampson, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338494/
https://www.ncbi.nlm.nih.gov/pubmed/25722935
http://dx.doi.org/10.4103/2152-7806.151341
_version_ 1782481226561486848
author Suryadevara, Carter M.
Verla, Terence
Sanchez-Perez, Luis
Reap, Elizabeth A.
Choi, Bryan D.
Fecci, Peter E.
Sampson, John H.
author_facet Suryadevara, Carter M.
Verla, Terence
Sanchez-Perez, Luis
Reap, Elizabeth A.
Choi, Bryan D.
Fecci, Peter E.
Sampson, John H.
author_sort Suryadevara, Carter M.
collection PubMed
description Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12–15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can be highly toxic by causing nonspecific damage to healthy brain and other tissues. The shortcomings of standard-of-care have thus created a stimulus for the development of novel therapies that can target central nervous system (CNS)-based tumors specifically and efficiently, while minimizing off-target collateral damage to normal brain. Immunotherapy represents an investigational avenue with the promise of meeting this need, already having demonstrated its potential against B-cell malignancy and solid tumors in clinical trials. T-cell engineering with tumor-specific chimeric antigen receptors (CARs) is one proven approach that aims to redirect autologous patient T-cells to sites of tumor. This platform has evolved dramatically over the past two decades to include an improved construct design, and these modern CARs have only recently been translated into the clinic for brain tumors. We review here emerging immunotherapeutic platforms for the treatment of MG, focusing on the development and application of a CAR-based strategy against GBM.
format Online
Article
Text
id pubmed-4338494
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43384942015-02-26 Immunotherapy for malignant glioma Suryadevara, Carter M. Verla, Terence Sanchez-Perez, Luis Reap, Elizabeth A. Choi, Bryan D. Fecci, Peter E. Sampson, John H. Surg Neurol Int Surgical Neurology International: Neuro-Oncology Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12–15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can be highly toxic by causing nonspecific damage to healthy brain and other tissues. The shortcomings of standard-of-care have thus created a stimulus for the development of novel therapies that can target central nervous system (CNS)-based tumors specifically and efficiently, while minimizing off-target collateral damage to normal brain. Immunotherapy represents an investigational avenue with the promise of meeting this need, already having demonstrated its potential against B-cell malignancy and solid tumors in clinical trials. T-cell engineering with tumor-specific chimeric antigen receptors (CARs) is one proven approach that aims to redirect autologous patient T-cells to sites of tumor. This platform has evolved dramatically over the past two decades to include an improved construct design, and these modern CARs have only recently been translated into the clinic for brain tumors. We review here emerging immunotherapeutic platforms for the treatment of MG, focusing on the development and application of a CAR-based strategy against GBM. Medknow Publications & Media Pvt Ltd 2015-02-13 /pmc/articles/PMC4338494/ /pubmed/25722935 http://dx.doi.org/10.4103/2152-7806.151341 Text en Copyright: © 2015 Suryadevara CM. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Surgical Neurology International: Neuro-Oncology
Suryadevara, Carter M.
Verla, Terence
Sanchez-Perez, Luis
Reap, Elizabeth A.
Choi, Bryan D.
Fecci, Peter E.
Sampson, John H.
Immunotherapy for malignant glioma
title Immunotherapy for malignant glioma
title_full Immunotherapy for malignant glioma
title_fullStr Immunotherapy for malignant glioma
title_full_unstemmed Immunotherapy for malignant glioma
title_short Immunotherapy for malignant glioma
title_sort immunotherapy for malignant glioma
topic Surgical Neurology International: Neuro-Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338494/
https://www.ncbi.nlm.nih.gov/pubmed/25722935
http://dx.doi.org/10.4103/2152-7806.151341
work_keys_str_mv AT suryadevaracarterm immunotherapyformalignantglioma
AT verlaterence immunotherapyformalignantglioma
AT sanchezperezluis immunotherapyformalignantglioma
AT reapelizabetha immunotherapyformalignantglioma
AT choibryand immunotherapyformalignantglioma
AT feccipetere immunotherapyformalignantglioma
AT sampsonjohnh immunotherapyformalignantglioma